Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?

Eur Urol. 2014 Apr;65(4):673-4. doi: 10.1016/j.eururo.2013.11.049. Epub 2013 Dec 25.

Abstract

The results reported in all trials comparing chronic versus on-demand phosphodiesterase type 5 inhibitor use after bilateral nerve-sparing radical prostatectomy may be affected by improper patient selection. Targeting the right patients is the key to optimizing the efficacy of these drugs.

Publication types

  • Editorial

MeSH terms

  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / rehabilitation*
  • Humans
  • Male
  • Organ Sparing Treatments
  • Patient Selection
  • Penis / innervation
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Prostatectomy / adverse effects*
  • Prostatectomy / methods*

Substances

  • Phosphodiesterase 5 Inhibitors